(b) an isolated nucleic acid molecule encoding an amino acid sequence comprising the sequence of SEQ ID NO:2 or SEQ ID NO:4;

(c) an isolated nucleic acid molecule that hybridizes to either strand of a denatured, double-stranded DNA comprising the nucleic acid sequence of (a) or (b) under conditions of moderate stringency in 50% formamide and 6XSSC, at 42°C with washing conditions of 60°C, 0.5XSSC, 0.1% SDS;

(d) an isolated nucleic acid molecule derived by in vitro mutagenesis from SEQ ID NO:1 or SEQ ID NO:3; or

(e) an isolated nucleic acid molecule degenerate from SEQ ID NO:1 or SEQ ID NO:3 as a result of the genetic code.

2. (original) A recombinant vector that directs the expression of the nucleic acid molecule of claim 1.

3. (original) An isolated polypeptide encoded by the nucleic acid molecule of claim 1.

4. (original) Isolated antibodies that bind to a polypeptide of claim 3.

5. (original) Isolated antibodies according to claim 4, wherein the antibodies are monoclonal antibodies.

6. (original) A host cell transfected or transduced with the vector of claim 2.

7. (original) A method for the production of an RGL polypeptide comprising culturing a host cell of claim 6 under conditions promoting expression, and recovering the polypeptide from the culture medium.

8. (original) The method of claim 7, wherein the host cell is selected from the group consisting of bacterial cells, yeast cells, plant cells, and animal cells.

9. (currently amended) The ~~composition~~ polypeptide of claim 3 ~~further~~ in a composition comprising a pharmaceutically acceptable carrier selected from the group consisting of

water, oils, alcohols, salts, fatty acids, saccharides, polysaccharides and combinations thereof.

10.-12. (canceled)

13. (original) An isolated RGL receptor protein or portion thereof which binds to the polypeptide of claim 1.

14.-33. (canceled)

34. (currently amended) A hybridoma which produces the monoclonal antibody of claim ~~33~~ 5.

35. (currently amended) A diagnostic kit comprising the antibody of claim ~~32~~ 4 for the detection of neoplastic disease.

36. (original) The kit of claim 35 wherein the neoplastic disease is a genitourinary cancer or metastatic disease.

37. (original) The kit of claim 36 wherein the genitourinary cancer or metastatic disease is prostate cancer.

38. (original) A vaccine comprising at least a portion of the polypeptide of SEQ ID NO: 4.

39. (currently amended) A method for treating a patient comprising administering to the patient a therapeutically effective amount of a composition comprising at least an active portion of the polypeptide of SEQ ID NO:2 or SEQ ID NO: 4.

40. (original) The method of claim 39 wherein the polypeptide has anti-neoplastic activity.

41. (original) The method of claim 40 wherein the anti-neoplastic activity is a modulation of chemokine expression.

42. (original) The method of claim 40 wherein the anti-neoplastic activity is a modulation of cytokine expression.

43. (original) The method of claim 39 wherein the therapeutically effective amount of the composition is administered locally to a tumor site, systemically, or parenterally.

44.-52 (canceled)

53. (currently amended) A method for treating a patient with a metastatic disorder comprising administering to the patient a therapeutically effective amount of a composition comprising at least a portion of the nucleotide of SEQ ID NO: 1 or SEQ ID NO:3.

54. (original) The method of claim 53 wherein the nucleotide encodes a polypeptide which has anti-neoplastic activity.

55. (original) The method of claim 54 wherein the anti-neoplastic activity is a modulation of chemokine expression.

56. (original) The method of claim 54 wherein the anti-neoplastic activity is a modulation of cytokine expression.

57. (original) The method of claim 53 wherein the therapeutically effective amount of the composition comprises an adenoviral vector.

58.-62. (canceled)

63. (new) The polypeptide of claim 3 wherein the polypeptide has an anti-neoplastic activity.